Effect of octreotide on small intestinal motility in HIV-infected patients with chronic refractory diarrhea

Digestive Diseases and Sciences

Volumn 46, Issue 12, 2001, Pages 2636-2642

  Neild, P J ^a   Evans, D F ^b   Castillo, F D ^a   Newson, R ^a   Yasaki, E T ^b   Wingate, D L ^b   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diarrhea; HIV; Octreotide; Small intestinal motility

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; OCTREOTIDE; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CHRONIC DIARRHEA; CLINICAL ARTICLE; DRUG EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE MOTILITY; MANOMETRY; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ADULT; ANTIDIARRHEALS; CHRONIC DISEASE; DIARRHEA; GASTROINTESTINAL MOTILITY; HIV INFECTIONS; HUMANS; MANOMETRY; MIDDLE AGED; OCTREOTIDE; POSTPRANDIAL PERIOD;

EID: 0035211412     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012706908623     Document Type: Article

References (45)

1. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients
2. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS
3. Gastrointestinal manifestations of HIV infection
4. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhea
5. Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS
6. Autonomic denervation in jejunal mucosa of homosexual men infected with HIV
7. Abnormal gastrointestinal (GI) motility in patients with human immunodeficiency virus 1 (HIV-1)
8. Consensus statement: Octreotide dose titration in secretory, diarrhea
9. Octreotide in gastrointestinal motility disorders
10. Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders
11. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmodynamic effects
12. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel
13. Effect of octreotide on refractory AIDS-associated diarrhea
14. Investigation of chronic diarrhea in acquired immunodeficiency syndrome. A prospective study of 155 patients
15. The computer as a referee in the analysis of small bowel motility
16. Jejunal manometry patterns in health, partial intestinal obstruction and pseudoobstruction
17. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
18. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma
19. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis
20. Somatostatin 28 and coupling of human interdigestive intestinal motility and pancreatic secretion
21. Somatostatin and the interdigestive migrating motor complex in man
22. Effect of somatostatin on gallbladder volume and small intestinal motor activity in humans
23. Effects of octreotide on manometric variables in patients with neuropathic abnormalities of the small bowel
24. Somatostatin induces interdigestive intestinal motor and secretory complex-like activity in man
25. Pilot study of sandostatin (octreotide) therapy of refractory HIV-associated diarrhea
26. Efficacy of octreotide in the management of chronic diarrhea in AIDS
27. Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex
28. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea
29. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion
30. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumours
31. Use of somatostatin analog in management of carcinoid syndrome
32. NIH conference: Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
33. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation
34. Octreotide in dumping and short bowel syndromes
35. Effective treatment of diabetic diarrhea with somatostatin analogue, octreotide
36. VIPoma syndrome: Effect of a synthetic somatostatin analogue
37. Vasoactive intestinal peptide 1-12: A ligand for the CD4 (T4) human immunodeficiency virus receptor
38. Neuronal cell killing by the envelope protein of HIV and it's prevention by vasoactive intestinal peptide
39. Peptides of human immunodeficiency virus (HIV) evoke rat colonic electrolyte secretion inhibitable by the somatostatin analog octreotide
40. Detection of HIV-1 protein and nucleic acid in enterochromaffin cells of HIV-1 seropositive patients
41. Autonomic function and human immunodeficiency virus infection
42. Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome
43. Differential regional effects of octreotide on human gastrointestinal motor function
44. Role of motility in intestinal transit and absorption